INTEGER HOLDINGS CORP

Company Overview

Integer Holdings Corporation is a global medical-technology CDMO (brands include Greatbatch Medical and Lake Region Medical) that designs, develops and manufactures custom components, subassemblies and finished devices across three principal lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation, and Other Markets. The firm sells mainly to large OEMs (Abbott, Boston Scientific and Medtronic together ~47% of revenue), operates manufacturing/engineering sites across the U.S., Mexico, Ireland and Asia, and maintains a ~$728M backlog with roughly 55% of shipments to U.S. locations. Recent years have shown mid-single-digit to double-digit top-line growth (2024 sales $1.717B), margin expansion from scale and efficiency, tuck‑in acquisitions to add capabilities, and rising leverage after sizeable acquisition and convertible note activity (net debt roughly $990M–$1.2B, total net leverage ~2.3x–2.7x).

Executive Compensation Practices

Compensation is likely tied to operational and financial metrics that reflect the CDMO model: revenue growth (product ramps and OEM order flow), gross margin/adjusted EBITDA or operating income (manufacturing leverage and cost efficiency), and free cash flow or cash conversion given the capital and working‑capital profile. Long‑term incentives will probably emphasize multi‑year targets such as ROIC, integration milestones from tuck‑in M&A, IP/product development milestones and quality/regulatory outcomes (FDA/EU‑MDR compliance, complaint/warranty rates), with typical mixes of base salary, annual cash bonus and equity (RSUs, performance shares or options). Given recent acquisitions, inducement/retention awards and deal-related vesting adjustments are also likely; management may use adjusted metrics (excluding acquisition costs, one‑time conversion charges) when setting incentive payouts.

Insider Trading Considerations

High customer concentration, frequent tuck‑in M&A and regulatory milestones make certain types of material nonpublic information more common — e.g., large OEM order changes, new product ramps, regulatory approvals or manufacturing issues — so trading activity around earnings, customer announcements and FDA/CE events merits close monitoring. The company’s recent convertible note issuance, debt movements and rising leverage can influence insiders’ diversification needs and timing of trades (and may also create derivative/hedging activity by holders), while equity vesting and tax obligations commonly drive scheduled sales. Expect standard corporate controls: Section 16 reporting (Form 4) filings, blackout windows around earnings and material events, and increased use of 10b5‑1 plans; watch for insider sales that coincide with acquisition closes, convertible financings, or large customer disclosures as potential signals.